Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Daratumumab consolidation therapy in MM

Alessandro Gozzetti • 14 Sep 2019
IMW 2019
Multiple Myeloma Daratumumab

Alessandro Gozzetti, MD, PhD, Sense University Hospital, Siena, Italy, discusses the use of daratumumab as consolidation therapy, in particular after autologous STEM cell transplantation in multiple myeloma (MM) patients, speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Alessandro Gozzetti

1:31
Early relapse prediction in myeloma treated with novel agents
Alessandro Gozzetti • 24 Feb 2021
1:37
FORTE: MRD negativity as key prognostic factor in NDMM
Alessandro Gozzetti • 24 Feb 2021
2:09
DART4MM: daratumumab in myeloma patients with VGPR to first-line therapy
Alessandro Gozzetti • 24 Feb 2021
2:41
Effect of daratumumab on MRD measured by NGF in myeloma
Alessandro Gozzetti • 27 Nov 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals